Pharmaceuticals

Vigabatrin-Related Retinal Toxicity

Patients taking this medication for epilepsy should be monitored carefully for visual disturbances.

Natalia Londoño De Vivero, MD; Rafael Méndez Marulanda, MD; Daniela Rojas Pérez, MD; Clemencia De Vivero Arciniegas, MD; and Álvaro Mejía Vergara, MD

Using PPAR Agonists to Treat DR

This class of drugs warrants further investigation of its potential to mitigate microvascular damage and improve patient outcomes.

Tahir Ishrak Khan, MPharma, and Divya Balram Jha, MPharma

Treating Uveitis Today and Tomorrow

Many novel therapies are under investigation to treat noninfectious uveitis and uveitic macular edema.

Yesde Esther Son, MD, PhD, and Tedi Begaj, MD

The Pipeline: TL;DR

Allen C. Ho, MD, and Robert L. Avery, MD

Nutritional Supplementation for IRDs: Preservation or Placebo?

Recent evidence suggests some benefits, but more work is needed.

Paula Morales, MD; Cesar Estrada-Puente, MD; and Ramiro Maldonado, MD

Implantable Drug Delivery: A Look At Pharmacokinetics

Novel approaches are showing promise for addressing treatment burden in retinal disease.

Charles C. Wykoff, MD, PhD, FASRS, FACS

Acute Retinopathy Following Weightlifting Supplement

An unusual case demonstrates the value of inquiring about a patient’s lifestyle and nutrition in relation to their visual symptoms.

Sayena Jabbehdari, MD, MPH, MBA; Abdelrahman M. Elhusseiny, MD, MSc; William A. Henry, MD; and Velimir Petrovic, MD

An Update on Sustained Drug Delivery in Retina

Unique ways to address treatment burden for patients with retinal conditions.

Deepak Sambhara, MD, and Marin Stowe, BS

Managing Wet AMD: The Promise of TKIs

This novel approach may help to mitigate the treatment burden associated with wet AMD therapy.

Rahul Iyengar, MD; Douglas Matsunaga, MD; and David S. Boyer, MD

Tailoring IVT Dosing With Vitreous Volume

We have heard the adage, “As much as necessary, as little as possible,” with regard to medication. Can we apply it to intravitreal therapy?

Andreas F. Borkenstein, MD

Retinal Capillary Hemangioblastomas in VHL

Case studies suggest a novel therapeutic may be able to treat these vision-threatening ocular tumors.

Corrina P. Azarcon, MD, DPBO; Imaan Zera Kherani, MD; and Amin Kherani, MD, FRCSC, FASRS

Managing The Ocular Effects of Steroid Overdose

Improper use to boost athletic performance caused this case of retinal vascular occlusion.

Fernando Godin, MD; Nimesh A. Patel, MD; Eduardo Cadena, MD; Diana Concha, MD; Maria Adelaida Piedrahita, MD; and Carolina Parra, MD

PVR Pipeline Roundup

At ASRS 2023, experts discussed two medical therapies under investigation.

Alex Brodin

Ocular Infection With Scedosporiosis Apiospermum

This chorioretinal infection was responsive to combination intravitreal and systemic antifungal therapy.

Dylan Sadowsky, MD; Justin Shortell, MD; and Ryan Leite, MD

Thioridazine Retinal Toxicity

Beware of this rare differential when faced with what seems to be an atypical case of AMD.

David Grasic, MD; Jorge A. Fortun, MD; and Luis J. Haddock, MD

A Toxic Side Effect of Dropless Surgery

Be careful of potentially toxic compounds found in some triamcinolone-moxifloxacin injections used in cataract surgery in place of postoperative drops.

Kishan G. Patel, MD, and Ashkan M. Abbey, MD

The Path to Product Launch

Experts share their four-step approach to product development and commercialization.

Steve Charles, MD, FACS, FICS, and Adam Pflugrath, MD

Clinical Trials Targeting RVO

New therapeutics under investigation are showing promise for the treatment of retinal vein occlusion.

Jessica Lee, BS; Linnet Rodriguez, MD; Meera D. Sivalingam, MD; and Yoshihiro Yonekawa, MD

What’s in the Works for Wet AMD

Researchers are pushing forward with novel therapeutics and delivery approaches.

Meghana Kalavar, MD; Dante Pieramici MD; and Nika Bagheri, MD

Proceed with Caution

Allen C. Ho, MD, and Robert L. Avery, MD